Flunoxaprofen API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Flunoxaprofen API 66934-18-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Flunoxaprofen. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Flunoxaprofen
- Synonyms:
- flunoxaprofeno
- Cas Number:
- 66934-18-7
- DrugBank number:
- DB13317
- Unique Ingredient Identifier:
- UKU5U19W9M
General Description:
Flunoxaprofen is a chemical compound identified by the CAS number 66934-18-7. It is known for its distinct pharmacological properties and applications.
Classification:
Flunoxaprofen belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group, classified under the direct parent group Phenyl-1,3-oxazoles. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Azoles class, specifically within the Oxazoles subclass.
Categories:
Flunoxaprofen is categorized under the following therapeutic classes: Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Products for Vaginal Administration, Antirheumatic Agents, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Propionates, Sensory System Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Flunoxaprofen is a type of Analgesics
Analgesics are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that are commonly used to relieve pain. They are designed to alleviate discomfort by targeting the body's pain receptors or by reducing inflammation. Analgesics are widely utilized in the medical field to manage various types of pain, ranging from mild to severe.
One of the primary classes of analgesics is nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs work by inhibiting the production of prostaglandins, substances that contribute to pain and inflammation. This class includes well-known drugs like ibuprofen and naproxen. Another class of analgesics is opioids, which are derived from opium or synthetic compounds that mimic the effects of opium. Opioids act on the central nervous system to reduce pain perception and provide potent pain relief. Examples of opioids include morphine, codeine, and oxycodone.
Analgesics are available in various forms, such as tablets, capsules, creams, and injections, allowing for different routes of administration based on the patient's needs. They are commonly used to manage pain associated with conditions like arthritis, headaches, dental procedures, and post-operative recovery.
It is important to note that analgesics should be used under medical supervision, as improper use or overuse can lead to adverse effects, including gastrointestinal complications, addiction, and respiratory depression in the case of opioids. Therefore, it is crucial for healthcare professionals to assess each patient's individual needs and prescribe the appropriate analgesic and dosage.
In summary, analgesics are a vital category of pharmaceutical APIs used to alleviate pain by targeting pain receptors or reducing inflammation. With various classes and forms available, they provide valuable options for pain management when used responsibly and under medical guidance.
